Thetis Receives $2.3 Million NIH Grant to Develop Immuno-Resolving Therapy for IBD

  Resolvin-based agent targets inflammation resolution and tissue regeneration without immunosuppression BRANFORD, CT – (GlobeNewswire – November 16, 2017) – Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). […]

Thetis Announces Pre-Clinical Data on TP-252

Preclinical data shows equivalence of TP-252 and EPA-FFA in modulating inflammatory eicosanoid profiles within the colon EPA-FFA has demonstrated clinical efficacy in reducing the rate of relapse in ulcerative colitis BRANFORD, CT May 8, 2017 – Thetis Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs for inflammatory bowel disease (IBD), today announced pre-clinical data […]

Thetis Announces Immuno-Resolving Therapies for Inflammatory Bowel Disease

– Lead candidate TP-252 expected to begin clinical studies in 2018 BRANFORD, CT– (May 5, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing small molecule drugs for treatment of gastrointestinal diseases, announced two development candidates, TP-252 and TP-317, for treatment of inflammatory bowel disease (IBD). Gary Mathias, co-founder and chief executive officer, commented, […]

Thetis Awarded Key Patent on HEALER Technology

SOUTHPORT, CT–(Marketwired – Jan 27, 2016) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for our lead development candidates, TP-252 for familial adenomatous polyposis. The allowed claims include pharmaceutical compositions that are mineral amino-acid […]

Thetis Expands HEALER Technology Patent Estate

SOUTHPORT, Connecticut, June 20, 2014—Thetis Pharmaceuticals LLC (“Thetis”), an emerging biopharmaceutical company focused on cardio-metabolic diseases, announced today the filing of two patent applications that broaden its foundation for identification and selection of multiple new therapeutic compounds for development. The patents expand the company’s HEALER℠ Technology (High Efficiency Amino Lipid Enabled Release) with proprietary amino-lipid […]